TY - JOUR

T1 - Effect of lorcaserin on glycemic parameters in patients with type 2 diabetes mellitus

AU - Magkos, Faidon

AU - Nikonova, Elena

AU - Fain, Randi

AU - Zhou, Sharon

AU - Ma, Tony

AU - Shanahan, William

N1 - © 2017 The Obesity Society.

PY - 2017

Y1 - 2017

N2 - Objective: Lorcaserin, a 5-HT2C receptor agonist approved for chronic weight management, is also associated with improvements in glycemic parameters in patients with/without type 2 diabetes mellitus (T2DM), but the extent to which these effects are mediated by weight loss is unknown. This post hoc analysis further examines glycemic data from the Phase III BLOOM-DM study stratified by weight changes.Methods: Patients with T2DM were randomized to lorcaserin 10 mg twice daily or placebo. Glycemic parameters were reported by Week (W) 12 weight loss status ≥5% (Group ≥5%) or <5% (Group <5%). Glycemic parameter changes were analyzed using ANCOVA; the relationship between glycemic parameter changes and percent weight loss was assessed by simple regression modeling.Results: Group ≥5% receiving lorcaserin had greater improvements in fasting plasma glucose (FPG) at W2 (prior to significant weight loss) and greater improvements in glycated hemoglobin (HbA1c) at W12 versus placebo. These improvements were maintained through W52 (FPG, -29.3 mg/dL vs. -24.2 mg/dL; HbA1c, -1.2% vs. -1.1%). Group <5% treated with lorcaserin also had larger decreases in FPG (-28.3 mg/dL vs. -10.0 mg/dL) and HbA1c (-0.8% vs. -0.4%) at W52 versus placebo despite limited weight loss.Conclusions: Lorcaserin may have beneficial effects on glycemic control with or without weight loss.

AB - Objective: Lorcaserin, a 5-HT2C receptor agonist approved for chronic weight management, is also associated with improvements in glycemic parameters in patients with/without type 2 diabetes mellitus (T2DM), but the extent to which these effects are mediated by weight loss is unknown. This post hoc analysis further examines glycemic data from the Phase III BLOOM-DM study stratified by weight changes.Methods: Patients with T2DM were randomized to lorcaserin 10 mg twice daily or placebo. Glycemic parameters were reported by Week (W) 12 weight loss status ≥5% (Group ≥5%) or <5% (Group <5%). Glycemic parameter changes were analyzed using ANCOVA; the relationship between glycemic parameter changes and percent weight loss was assessed by simple regression modeling.Results: Group ≥5% receiving lorcaserin had greater improvements in fasting plasma glucose (FPG) at W2 (prior to significant weight loss) and greater improvements in glycated hemoglobin (HbA1c) at W12 versus placebo. These improvements were maintained through W52 (FPG, -29.3 mg/dL vs. -24.2 mg/dL; HbA1c, -1.2% vs. -1.1%). Group <5% treated with lorcaserin also had larger decreases in FPG (-28.3 mg/dL vs. -10.0 mg/dL) and HbA1c (-0.8% vs. -0.4%) at W52 versus placebo despite limited weight loss.Conclusions: Lorcaserin may have beneficial effects on glycemic control with or without weight loss.

KW - Adolescent

KW - Adult

KW - Aged

KW - Benzazepines/administration & dosage

KW - Blood Glucose/drug effects

KW - Diabetes Mellitus, Type 2/blood

KW - Double-Blind Method

KW - Female

KW - Glycated Hemoglobin A/analysis

KW - Humans

KW - Male

KW - Middle Aged

KW - Retrospective Studies

KW - Young Adult

U2 - 10.1002/oby.21798

DO - 10.1002/oby.21798

M3 - Journal article

C2 - 28345809

VL - 25

SP - 842

EP - 849

JO - Obesity

JF - Obesity

SN - 1930-7381

IS - 5

ER -